Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Henry Schein (NASDAQ:HSIC) in the last three months.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $82.2, with a high estimate of $90.00 and a low estimate of $75.00. Observing a 6.06% increase, the current average has risen from the previous average price target of $77.50.

Decoding Analyst Ratings: A Detailed Look

The perception of Henry Schein by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Henry Schein's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Henry Schein analyst ratings.

Get to Know Henry Schein Better

Henry Schein: Delving into Financials

Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.

Revenue Growth: Henry Schein displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 0.38%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Henry Schein's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 3.12%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Henry Schein's ROE excels beyond industry benchmarks, reaching 2.82%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Henry Schein's ROA stands out, surpassing industry averages. With an impressive ROA of 0.95%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: With a below-average debt-to-equity ratio of 0.85, Henry Schein adopts a prudent financial strategy, indicating a balanced approach to debt management.

The Significance of Analyst Ratings Explained

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.